Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Solid Biosciences Inc. before investing.

In this article, we go over a few key elements for understanding Solid Biosciences Inc.’s stock price such as:

• Solid Biosciences Inc.’s current stock price and volume
• Why Solid Biosciences Inc.’s stock price changed recently
• Upgrades and downgrades for SLDB from analysts
• SLDB’s stock price momentum as measured by its relative strength

About Solid Biosciences Inc. (SLDB)

Before we jump into Solid Biosciences Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Want to learn more about Solid Biosciences Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Solid Biosciences Inc..

Solid Biosciences Inc.’s Stock Price as of Market Close

As of June 11, 2025, 12:47 PM, CST, Solid Biosciences Inc.’s stock price was $4.670.

Solid Biosciences Inc. is down 3.31% from its previous closing price of $4.830.

During the last market session, Solid Biosciences Inc.’s stock traded between $4.610 and $4.900. Currently, there are approximately 66.34 million shares outstanding for Solid Biosciences Inc..

Solid Biosciences Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Solid Biosciences Inc. Stock Price History

Solid Biosciences Inc.’s (SLDB) price is currently up 45.48% so far this month.

During the month of June, Solid Biosciences Inc.’s stock price has reached a high of $5.070 and a low of $3.065.

Over the last year, Solid Biosciences Inc. has hit prices as high as $10.370 and as low as $2.410. Year to date, Solid Biosciences Inc.’s stock is up 16.75%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Solid Biosciences Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 10, 2025, there were 5 analysts who downgraded Solid Biosciences Inc.’s stock and 5 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Solid Biosciences Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Solid Biosciences Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Solid Biosciences Inc. (SLDB) by visiting AAII Stock Evaluator.

Relative Price Strength of Solid Biosciences Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 10, 2025, Solid Biosciences Inc. has a weighted four-quarter relative price strength of -13.10%, which translates to a Momentum Score of 16 and is considered to be Very Weak.

Want to learn more about how Solid Biosciences Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Solid Biosciences Inc. Stock Price: Bottom Line

As of June 11, 2025, Solid Biosciences Inc.’s stock price is $4.670, which is down 3.31% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Solid Biosciences Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.